841 Shares in Becton, Dickinson and Company (NYSE:BDX) Purchased by Horan Capital Advisors LLC.

Horan Capital Advisors LLC. bought a new stake in Becton, Dickinson and Company (NYSE:BDX) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 841 shares of the medical instruments supplier’s stock, valued at approximately $203,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Livelsberger Financial Advisory bought a new position in Becton, Dickinson and Company during the third quarter valued at $26,000. Ashton Thomas Securities LLC bought a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth $33,000. Tompkins Financial Corp increased its holdings in Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 46 shares during the last quarter. Sound Income Strategies LLC raised its stake in Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 44 shares during the period. Finally, Kennebec Savings Bank purchased a new stake in Becton, Dickinson and Company during the third quarter valued at about $46,000. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Trading Down 0.4 %

Shares of BDX stock opened at $224.14 on Tuesday. The company has a market capitalization of $64.79 billion, a PE ratio of 37.73, a price-to-earnings-growth ratio of 1.68 and a beta of 0.43. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $249.89. The business’s fifty day moving average is $236.03 and its 200 day moving average is $234.89. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter last year, the firm posted $3.42 EPS. The company’s revenue was up 6.9% compared to the same quarter last year. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 1.86%. The ex-dividend date of this dividend is Monday, December 9th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s payout ratio is currently 63.97%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on BDX shares. Raymond James reduced their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Stifel Nicolaus boosted their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Evercore ISI increased their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.